92 results about "Protein s antigen" patented technology

The invention relates beta-fordin antigen epitope polypeptide screening for gaining amino acid sequence corresponded with the optimum beta-fordin polypeptide. The beta-fordin antigent epitope polypeptide includes the following two that one is formed by the amino acid sequence showed in SEQ ID NO.1; another is derived from the above amino acid sequence by replacing, missing or adding one or many amino acid with antigen epitope function. It can used to specially test beta-fordin polypeptide IgG antibody for Sjogren syndrome patient. The invention also supplies the beta-fordin polypeptide IgG antibody immunology method, and its application used as antigen in Sjogren syndrome medicine preparation.

The invention discloses an antituberculous CTL (Cytotoxic T Lymphocyte) epitope peptide with a drug-resistant related efflux protein source for tuberculosis. The antituberculous CTL epitope peptide is nonapeptide, wherein the amino acid sequence of the nonapeptide is P9: ALGML IAGL. Predicative analysis is carried out on HLA-A*0210 restrictive CTL epitope of drug-resistant related protein antigen for tuberculosis by adopting immune-informatics means and SYFPEITH1, BIMAS and NetCTL1.2 databases according to the primary structure of the antigen, so that the epitope peptide is obtained by screening; and the identified nonapeptide has not been reported in any document. An in-virto ELISPOT (Enzyme-Linked Immunospot Assay) is adopted to identify the epitope peptide; and the identification result provides a theoretical basis for developing tuberculosis vaccine based on drug-resistant related protein antigen and provides more information for designing multi-epitope peptide vaccine for tuberculosi based on the mixed T cell epitope.

The invention discloses a COVID-19 rapid diagnosis kit. The COVID-19 rapid diagnosis kit comprises COVID-19 spike protein antigen colloidal gold. The invention also discloses a preparation method of the COVID-19 rapid diagnosis kit. The preparation method comprises the following steps: expressing and purifying COVID-19 spike protein; and preparing the COVID-19 spike protein antigen colloidal gold.The kit is simple to operate, can quickly diagnose whether a patient is infected with COVID-19 or not, and is beneficial to effective control of epidemic situations.

The invention belongs to the field of biological products, and relates to a composite vaccine for Alzheimer's disease prevention and treatment, wherein the composite vaccine is prepared by mixing a nucleic acid vaccine encoding Abeta42 and a protein gene engineering vaccine. Experiment results show that: Abeta42 protein antigen expressed through prokaryotic expression and pVAX-Abeta42 plasmid are adopted to co-immunize, such that the Alzheimer's disease protein vaccine in the prior art is improved, high level anti-Abeta antibody IgG can be produced, inhibition on T cell response can be induced, and the inhibition can be maintained for a fairly long time. In addition, the antibody generated through co-immunizing and for Abeta can be combined with Abeta protein fibers and nature Abeta protein precipitate in APP/PS1 Alzheimer's disease transgene incidence mice brain so as to provide Abeta precipitate removing capacity; and the vaccine is a potential, effective, and side effect-free vaccine, and can be used for Alzheimer's disease prevention and treatment.

The present invention relates to one kind of bivalent livestock type-A and type-O foot and mouth disease DNA vaccine. It is prepared through connecting serially the coding regions of the VP1 protein antigen determinants of both type-A and type-O foot and mouth disease virus strains, and the connection with DNA segment capable of raising the immunogenicity. The preparation process includes connecting enzyme incised segment with eukaryotic expression carrier and transforming competent colibacillus cell; PCR identification to obtain positive cloning; culturing, collecting thallus, cracking cell and centrifuging; and other steps. The bivalent livestock type-A and type-O foot and mouth disease DNA vaccine is used to immunize livestock to generate antibody resisting both type-A and type-O foot and mouth disease viruses. It has no pathogenetic effect and can induce the livestock body to generate comprehensive immune response and express modified natural antigen.

The invention relates to a specific Thr1861 site phosphorylated antigen peptide aiming at a human NOTCH1 NICD protein, an antibody, application of the antigen peptide and the antibody, and a preparation method of the antibody. The antibody is shown as SEQ ID NO:1 through an active amino acid sequence, Thr amino acid is phosphorylated and prepared as an antigen peptide immunized animal. When the antibody is prepared, antiserum is purified by utilizing an affinity purification-affinity separation technology. The preparation method has the advantages of being short in preparation period, high in antibody potency, good in recovery rate, and the like; the obtained antibody has high specificity and high affinity; the phosphorylated antibody is helpful to reveal an action mechanism of phosphorylation modification of the NOTCH1 NICD protein in the occurrence and development of tumors and other diseases, and has wide clinical application prospect in accepts of tumor diagnosis, treatment, prognosis judgment and the like.

The invention discloses a preparation method of a novel genetically recombinant pure protein antigen and relates to the technical field of protection of hemagglutinin viruses and development of detection reagents. The preparation process comprises the following steps: I, gene recombinant expression of a hemagglutinin H7 antigen; II, preparation of the hemagglutinin H7 antigen; III, application of the hemagglutinin pure protein to animals/human bodies; and IV, application of the high purity hemagglutinin H7 antigen to detecting hemagglutinin H7-containing viruses. The novel genetically recombinant pure protein antigen has the characteristics of high purity and good antigenicity, and does not exist in form of granules and not only does not contain any genetic materials such as RNA (Ribonucleic Acid), but also does not contain other protein impurities. The novel genetically recombinant pure protein antigen can be used for preparing a high specific antibody for H7N9. Because of the protein characteristic of the H7 antigen, the chromatographic method can be used for purifying a single antigen, and the purity of SEC-HPCL (Size Exclusion Chromatography-High Performance Liquid Chromatography) is higher than 90%. The high purity H7 antigen and the highly specific H7N9 antibody can be used for developing diagnostic reagents for diagnosing H7N9 avian influenza.

The invention provides a method for preparing a pET-28a-SUMO-coagulation factor II protein antigen and a polyclonal antibody thereof. According to the method, a grass carp coagulation factor II gene sequence is synthesized by using a grass carp coagulation factor II specific primer through a PCR amplification technology, then cloned into a pET-28a-SUMO expression vector, then delivered into E. coli Rosetta for expression and then purified to obtain the pET-28a-SUMO-coagulation factor II protein antigen, the antigen is used for repeated immunization of laboratory-scale Japanese white rabbits, blood sampling is carried out, antiserum is collected, pET-28a-SUMO-coagulation factor II protein is used as the antigen for affinity purification, and the concentrated grass crap coagulation factor IIpolyclonal antibody is obtained. The method can obtain the concentrated grass carp coagulation factor II polyclonal antibody meeting the requirements of subsequent experiments, thereby providing an important experimental reagent for the subsequent detection of the expression of the grass carp coagulation factor II.

The present invention provides a lateral flow test device for detecting a coronavirus antibody by immunoassay; the test device includes three lateral flow test strips; a first test strip is directed to the antibody detection of a N full-length protein and/or an S full-length protein antigens/antigen; and a second test strip is directed to the antibody detection of an S-RBD-site protein antigen, and both of the first strip and the second strip are combined to detect novel coronavirus IgG and IgM antibodies, which can practically reduce the possibility of missing detection and wrong detection; further, a third test strip is directed to the detection of a neutralizing antibody at an S-RBD site to rapidly detect the neutralizing antibody having protection effect, thus further helping the prevention of missing detection and helping patients to perform self-detection and judge the situations of recovery, or vaccine immunity.

The invention discloses a bovine respiratory syncytial cell virus antigen protein. Compared with SEQ 048055.1, an amino acid sequence of the bovine respiratory syncytial cell virus antigen protein is provided with at least two loci substituted by cysteines, the substitutive cysteines are connected through a disulfide bond, improvements such as internal disulfide bond, hole filling and single stranded connection are also performed on the basis, and meanwhile a preparation method of the antigen protein is provided. The antigen protein applies the technique and theory of protein crystallography, the structural change of the protein in virus infection and pathopoiesis process is determined, and then genetic engineering modification is conducted on the key virus protein according to a structural change result, so that the protein becomes a protein antigen only infecting without pathopoiesis and causing efficient reaction of animal body antibodies. The antigen protein can effectively prevent and treat bovine respiratory syncytial cell virus infection, an ideal viral vaccine can be developed on the basis, loss brought by virus inflection can be effectively controlled and prevented, and the antigen protein has great economic significance and social significance.